═══════════════════════════ SERVICE TIERS & PRICING
Transparent Investment. Predictable Deliverables. ═══════════════════════════
We've productized exploratory toxicology to eliminate the "quote-lag" of traditional CROs. Choose the tier that matches your data requirements, know your investment upfront, and launch your study with confidence.
*All pricing is per compound for standard mouse/rat protocols.
*Large animal studies and custom designs quoted separately.
THREE STANDARDIZED SERVICE TIERS
Imaging Only
$150K / candidate
Systemic Bio-distribution
Standard Integration
$200K / candidate
Integrated Validation
⭐Most Popular⭐
Comprehensive Discovery
$250K / candidate
The "Total Truth" Suite
DETAILED COMPARISON TABLE
IMAGING ONLY TIER - $150,000
Focused Whole-Body Imaging for Rapid Toxicity Screening
The Imaging Only tier is our high-throughput "Molecular Filter." It is specifically designed for drug discovery teams who need the precision of TITAN-RX™ molecular mapping but possess the internal infrastructure to handle their own terminal procedures and molecular biology downstream.
WHAT'S INCLUDED:
Whole-Body SPECT/CT Imaging:
- Temporal Precision: Baseline + treatment phase imaging (Days 1, 3, 5).
- Statistical Density: 12-14 animals per cohort, providing the p<0.05 threshold required for organ-specific uptake significance.
- TITAN 3D Coverage: Non-invasive longitudinal tracking within the same animals. This reduces biological noise and adheres to 3Rs (Reduction) principles by using the subject as its own control.
Quantitative Intelligence:
- Organ-Specific Uptake Quantification: Precise uptake measurement across all major organ systems (CNS, Cardiac, Hepatic, Renal, etc.). Fold-change calculations vs. baseline
- Fold-change Analyses: Automated calculation of signal intensity versus baseline control data to identify acute onset tissue damage (includes statistical analyses (p-values, confidence intervals)
- Tissue-by-Tissue Damage Ranking: A prioritized list of organ susceptibility including tissue-by-tissue damage ranking to identify "hidden" off-target signals to inform your secondary screening strategy
Standard Observations:
- Continuous Clinical Monitoring: Daily body weight, behavioral assessments (posture, grooming, activity), tumor volume (if applicable), and mortality monitoring.
Deliverables:
- Comprehensive Imaging Analysis Report: Detailed breakdown of all functional signals.
- 4D Visualization Suite: High-resolution, publication-quality figures and 4D video files for internal presentations and investor updates.
- Regulatory-Ready Data: SEND-compatible data exports ready for integration into your Pre-IND briefing materials.
- PhD Consultation: A 60-minute technical session to review findings and map out the Stage 2 GLP strategy.
Animal Disposition (Customer Choice):
- OPTION A: Live Transfer. Animals are returned to your facility after the Day 5 imaging session. This allows you to perform in-house terminal procedures, such as specialized tissue harvesting or gene expression profiling, at your preferred timepoint. (Note: Requires an active IACUC protocol at the receiving facility; verification is required prior to study launch.)
- OPTION B: In-House Termination. Animals are humanely terminated by Durametrix at Day 5. This option is ideal for rapid "Yes/No" screening where tissue retention is not required.
Scheduling:
- Imaging Timepoints: can be customized based on your compound and study design (e.g., Days 2, 4, 6 instead of 1, 3, 5)
Timeline:
- TOTAL TIMELINE: 12-14 weeks from pipeline integration to report delivery.
Best For:
- Companies with established in-house histopathology or molecular biology labs.
- Rapidly screening 10+ leads to find the "Top 3" for further investment.
- Exploratory studies where functional imaging is the primary required endpoint.
- Customers who prefer to control tissue analysis downstream.
*Pricing is based on standard rodent models (Mouse/Rat) and established tracer protocols. Custom studies quoted separately. Final investment is contingent on project complexity, specific tracer requirements, and study depth.*
*Pipeline and Project packages assume a standardized protocol across the compound library to maximize operational efficiency.*
*TITAN™ deliverables are for exploratory research and discovery purposes only. All off-target and collateral tissue findings are intended to guide internal R&D decisions and do not constitute a formal regulatory toxicology conclusion.*
⭐STANDARD INTEGRATION TIER⭐ — $200,000
Most Popular! - Complete Biomarker Integration with Optional Tissue Preservation
The "Predictive Advantage" Tier. This package is designed to bridge the gap between functional imaging and traditional clinical markers. By correlating Noceravide™ signals with blood chemistry in the same subjects, we identify toxicity "lead times"—often detecting organ stress days before clinical biomarkers spike.
WHAT'S INCLUDED:
Everything in Imaging-Only, PLUS:
Extended Imaging & Temporal Depth:
- Day 7 Endpoint: Imaging on Days 1, 3, 5, and 7. The additional timepoint is critical for capturing delayed-onset toxicity or observing early recovery kinetics.
- Matched Timepoints: Clinical biomarkers are collected alongside every imaging session, ensuring perfect temporal correlation between molecular damage and systemic response. Clinical biomarkers are collected alongside every imaging session, enabling direct temporal alignment and correlation of molecular tissue responses with systemic biomarkers.
Clinical Chemistry (CMP) & Hematology (CBC):
- Comprehensive Metabolic Panel: Full metabolic profiling, including Liver (ALT/AST), Kidney (BUN/Creatinine), and Electrolytes.
- Complete Blood Count with Differential: 5-part differential to detect myelosuppression, immune modulation, and anemia.
- Longitudinal Trends: We don't just provide a snapshot; we map the velocity of change across the 7-day window.
Integrated Correlation Analysis:
-The "Lead/Lag" Report: Our scientists identify the specific moment imaging signals deviate from the baseline versus when traditional biomarkers elevate.
-Mechanistic Insight: Identify if tissue damage is localized (imaging signal only) or has reached systemic significance (biomarker elevation).
ENHANCED Deliverables:
- Tri-Modal Analytics: Imaging, Chemistry, and Hematology data integrated into a single, side-by-side longitudinal report.
- Interactive Trend Graphs: High-resolution visualizations of biomarker velocity mapped against 3D organ uptake.
OPTIONAL TISSUE PROCESSING & PRESERVATION:
- Option A:
-
Live Transfer. Animals returned to your facility after Day 7 imaging.*
- Option B:
-
Terminated with Professional Harvest. Includes complete tissue harvest of all major organs.
-
Custom Preservation: Your choice of Formalin Fixation (for downstream histology) or Cryopreservation (for RNA-seq, proteomics, or immunoassays).
-
Sample Logistics: All preserved tissues are professionally packaged and shipped to your facility for final analysis.
Scheduling:
- Imaging Timepoints: can be customized based on your compound and study design (e.g., Days 2, 4, 6, 8 instead of 1, 3, 5, 7).
Timeline:
- TOTAL TIMELINE: 12-14 weeks from pipeline integration to report delivery.
Best For:
- Candidate Selection: Comparing 2-3 leads using identical, high-density metrics.
- Regulatory Preparation: Building a robust data package for Pre-IND discussions.
- Mechanism of Action (MoA) Discovery: Understanding the systemic impact of observed tissue damage.
- Extending studies where the basic package is insufficient
COMPREHENSIVE TIER — $250,000
Maximum Exploratory Detail — Multi-Modal Imaging with Full Histopathology
The "Gold Standard" Validation. This tier is engineered for high-stakes decision points, such as Final Lead Selection or Pre-IND briefing packages. By combining functional SPECT, high-resolution anatomical MRI, clinical biomarkers, and expert pathology, we provide a 360-degree safety profile that leaves no room for ambiguity.
WHAT'S INCLUDED:
Everything in Standard Integration, PLUS:
Advanced Multi-Modal Imaging (SPECT/CT + MRI):
- High-Field MRI Correlation: Anatomical MRI at every timepoint (Days 1, 3, 5, 7). While SPECT/CT detects functional stress, MRI provides superior soft-tissue contrast to visualize structural changes.
- Precision Overlays: We provide co-registered SPECT/MRI figures, allowing you to see exactly where Noceravide™ signals align with anatomical structures.
Full Histopathology & Pathologist Review:
- Gold-Standard Staining: Full H&E (Morphology) and TUNEL (Apoptosis/Cell Death) staining across all major organ systems.
- Board-Certified Assessment: All slides are reviewed by a Board-Certified Veterinary Pathologist. Deliverables include organ-level scoring, grading, and a comprehensive narrative report.
- Spatial Truth: We correlate "hot spots" found in 3D imaging directly with the microscopic findings on the slide.
Unstained Sections for Custom Analysis:
- Future-Proofing: We provide 2 unstained tissue sections from your tissues of interest. This allows your team to perform custom IHC, RNA-seq, or proprietary staining at a later date without restarting the study.
THE COMPREHENSIVE MULTI-MODAL REPORT:
- Total Integration: A single, master report aligning SPECT/CT signal, MRI anatomy, Clinical Biomarkers (CBC/CMP), and Histopathology findings by organ and timepoint.
- Investor-Ready Figures: Publication-quality, integrated figures designed to build maximum confidence during board meetings, partnering discussions, or regulatory Pre-IND briefings.
Timeline:
- TOTAL TIMELINE: 12–14 weeks total. (Note: The addition of MRI and Pathology is streamlined within our standard workflow to maintain your competitive timeline).
Best For:
- IND-Supportive Validation: Building the "Safety Case" for regulatory bodies.
- High-Stakes Investor Due Diligence: Providing the highest level of preclinical "Proof of Safety."
- Mechanistic Confirmation: Using MRI and Pathology to confirm the exact nature of an imaging-detected toxicity signal.
- As of 2026, the FDA increasingly values "Multiple Lines of Evidence." This package is designed to satisfy such criteria by providing substantial comprehensive evidence.
- Extending studies where standard integration tier is insufficient and additional insights are required
VOLUME PRICING:
STRATEGIC PORTFOLIO SCALING
Accelerate Your Entire Pipeline While Reducing Per-Compound Investment
TITAN™ is most effective when deployed across your entire portfolio. By standardizing your exploratory toxicology, you eliminate variables between studies and gain the power to make objective, head-to-head safety comparisons across all candidates.
SIGNIFICANT SAVINGS FOR MULTI-COMPOUND PROGRAMS
PROJECT PACKAGE (10+ COMPOUNDS):
- $180,000 per compound
- 10% Reduction based on the Standard Integration tier.
- Total Investment: $1.8M for 10 compounds (vs. $2M single-study rate).
- STRATEGIC SAVINGS: $200,000
PIPELINE PACKAGE (20+ COMPOUNDS):
- $150,000 per compound
- 25% Reduction based on the Standard Integration tier.
- Total Investment: $3M for 20 compounds (vs. $4M single-study rate).
- STRATEGIC SAVINGS: $1,000,000
THE TITAN™ PORTFOLIO ADVANTAGE
Standardizing your pipeline with a multi-compound package provides technical benefits that individual studies cannot match:
THE STRATEGIC ADVANTAGE:
- Data Harmonization: We ensure consistent data structures across your entire portfolio, enabling direct head-to-head safety comparisons between different chemical scaffolds.
- Priority Pipeline Scheduling: Multi-compound programs receive "First-In-Line" status, ensuring your entire portfolio moves toward the IND milestone simultaneously.
- Dedicated Portfolio Manager: A single point of contact to manage logistics, timelines, and reporting across all 10 or 20+ studies.
- Synthesis Flexibility: We offer flexible scheduling to accommodate your chemistry team’s synthesis timeline—launching studies as soon as your mg-scale quantities are ready.
- Strategic Reviews: Includes quarterly progress reviews and data-driven planning sessions with our PhD staff to help you triage your leads based on emerging safety signals.
Note: Volume pricing shown is based on the Standard Integration tier. Imaging-Only and Comprehensive tiers are available at proportional discounts.
Have Questions About Pricing or Logistics?
Get the details on how we protect your timeline and your budget
Our [Comprehensive FAQ Page] covers everything you need to know to prepare for a TITAN-RX™ study:
- Financials: Payment terms, milestone billing, and pricing.
- Operations: Timeline contingencies and parallel-batch scheduling.
- Compliance: Animal disposition, IACUC requirements, and "Live Returns"
- Regulatory: Clarifications on 21 CFR § 312.23 (Non-GLP Exploratory Data).
View Pricing & Logistics In Our FAQ Page for more details.
OR
Schedule a Technical Call to speak directly with our PhD staff.